Recombinant adenovirus vectors for gene therapy and clinical trials (A review)

Nász, István and Ádám, Éva (2001) Recombinant adenovirus vectors for gene therapy and clinical trials (A review). Acta Microbiologica et Immunologica Hungarica, 48 (3-4). pp. 323-348. ISSN 1217-8950

Preview

Text amicr.48.2001.3-4.6.pdf Download (201kB) | Preview

Abstract

In the last decade adenovirus (AdV) vectors have emerged as promising technology in gene therapy. They have been used for genetic modification of a variety of somatic cells in vitro and in vivo. They have been widely used as gene delivery vectors in experiments both with curative and preventive purposes. AdV vectors have been used in the experimental and in some extent in the clinical gene therapy of a variety of cancers. The combination of recombinant AdV technology with chemotherapy (pro drug system) seems to be promising, too. AdV vectors offer several advantages over other vectors.  Replication defective vectors can be produced in very high titers (1011 pfu/ml) thus allowing a substantially greater efficiency of direct gene transfer; they have the capacity to infect both replicating and nonreplicating (quiescent) cells from a variety of tissues and species. Several important limitations of adenovirus mediated gene transfer are also known, such as the relatively short-term (transient) expression of foreign genes, induction of the host humoral and cellular immune response to viral proteins and viral infected cells, which may substantially inhibit the effect of repeated treatment with AdV vectors, the limited cloning capacity and the lack of target cell specificity. However, the well-understood structure, molecular biology and host cell interactions of AdV-s offer some potential solutions to these limitations.

Actions (login required)

Edit Item